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Abstract
Background: Ventilator-associated respiratory infection (VARI) comprises ventilator-associated pneumonia (VAP) and
ventilator-associated tracheobronchitis (VAT). Although their diagnostic criteria vary, together these are the most
common hospital-acquired infections in intensive care units (ICUs) worldwide, responsible for a large proportion of
antibiotic use within ICUs. Evidence-based strategies for the prevention of VARI in resource-limited settings are
lacking. Preventing the leakage of oropharyngeal secretions into the lung using continuous endotracheal cuff
pressure control is a promising strategy. The aim of this study is to investigate the efficacy of automated,
continuous endotracheal cuff pressure control in preventing the development of VARI and reducing antibiotic
use in ICUs in Vietnam.
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Methods/design: This is an open-label randomised controlled multicentre trial. We will enrol 600 adult patients
intubated for ≤ 24 h at the time of enrolment. Eligible patients will be stratified according to admission diagnosis
(180 tetanus, 420 non-tetanus) and site and will be randomised in a 1:1 ratio to receive either (1) automated,
continuous control of endotracheal cuff pressure or (2) intermittent measurement and control of endotracheal cuff
pressure using a manual cuff pressure meter. The primary outcome is the occurrence of VARI, defined as either VAP
or VAT during the ICU admission up to a maximum of 90 days after randomisation. Patients in both groups who
are at risk for VARI will receive a standardised battery of investigations if their treating physician feels a new
infection has occurred, the results of which will be used by an endpoint review committee, blinded to the allocated
arm and independent of patient care, to determine the primary outcome. All enrolled patients will be followed for
mortality and endotracheal tube cuff-related complications at 28 days and 90 days after randomisation. Other
secondary outcomes include antibiotic use; days ventilated, in ICU and in hospital; inpatient mortality; costs of
antibiotics in ICU; duration of ICU stay; and duration of hospital stay.
Discussion: This study will provide high-quality evidence concerning the use of continuous endotracheal cuff
pressure control as a method to reduce VARI, antibiotic use and hospitalisation costs and to shorten stay.
Trial registration: ClinicalTrials.gov, NCT02966392. Registered on November 9, 2016. Protocol version: 2.0;
issue date March 3, 2017.
Keywords: Intensive care unit, Ventilator-associated pneumonia, Intubation, Tracheal tube cuff pressure,
Hospital-acquired infection
Background
Hospital-acquired infections (HAIs) are the most common
adverse events affecting hospitalised patients; over 700,000
occur in the United States every year, impacting length of
hospital stay, cost and mortality [1]. A point prevalence sur-
vey of HAI among nearly 20,000 patients from 23 European
countries in 2010 showed an HAI prevalence of 7.1%, with
the highest prevalence being in intensive care units (ICUs)
(28.1%) [2]. Pneumonia and other lower respiratory tract
infections were the most common types of HAI, account-
ing for 25.7% of all HAIs [2]. HAIs were also the second
most frequent indication for antibiotic treatment, with 24%
of all antibiotic use being for this indication. Respiratory in-
fection accounted for 24.8% of HAI-related antibiotic use
[2]. Data on HAIs for low- and middle-income countries
(LMICs) are sparse, but they indicate that the problem is
even greater in this setting with the highest burden in ICUs
[3]. In Vietnam HAI prevalence in ICUs has been estimated
to be as high as 30%, with up to 80% attributed to pneumo-
nia and lower respiratory tract infection. High rates of
broad-spectrum antibiotic use have resulted in very high
levels of antibiotic resistance, especially among gram-
negative bacteria [4], further necessitating the use of expen-
sive, broad empirical therapy for HAI and contributing to
the problem of antibiotic resistance. Most HAIs acquired
on ICUs are ventilator-associated respiratory infections
(VARIs) [1, 3]. A substantial reduction in this would pro-
vide direct benefit to patients and their families through
shorter stay, reduced costs and potentially reduced mortal-
ity. Importantly, it would also reduce antibiotic use, a key
driver of antimicrobial resistance.
Critical in the pathogenesis of lung infections in intu-
bated patients is the movement of contaminated oropha-
ryngeal secretions into the lungs [5, 6]. This may occur
through passage internally, down the lumen of the tube,
or externally around the outside of the tube, bypassing
the endotracheal tube cuff. To address this, several strat-
egies have been trialled, such as antibiotic decontamin-
ation of the oropharynx [7] (to address internal and
external routes) and intermittent or continuous suction-
ing of secretions (subglottic suctioning, to address
external routes) [8]. However, the use of antibiotic de-
contamination of the oropharynx, often with colistin,
may cause problems in settings where infection control
is limited and antibiotic resistance has reached the point
that colistin is the only remaining option for many infec-
tions, or where colistin resistance among gram-negative
bacteria has already emerged or been selected for. In
such settings the generation and further spread of
colistin-resistant gram-negative bacteria would be cata-
strophic, both locally and internationally. Additionally,
both oropharyngeal decontamination and intermittent
suctioning are labour-intensive and difficult to imple-
ment in settings where nurse-to-patient ratios are low.
Temporary falls in endotracheal cuff pressure may be
a critical factor for the entry of upper airway secretions
into the distal airways and lungs [6] and under-inflation
of the endotracheal cuff has been associated with in-
creased incidence of ventilator-associated pneumonia
(VAP) in observational studies, with one study showing
an OR of 4.3 for VAP in those patients with cuff pres-
sure consistently < 20 mmHg [9]. Continuous pressure
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control (CPC) minimises the periods of low cuff pressure,
preventing leakage of accumulated secretions that have
pooled above the cuff, whilst also preventing high pressure
that can cause tracheal injury. CPC is performed with de-
vices that are widely used in the United States and Europe,
with several devices available in Vietnam, although data
supporting their use as a means of reducing VARI or VAP
are relatively sparse. These devices use one of two means
to maintain endotracheal cuff pressure at a given level: (1)
several commercially available devices use an electric
pump and electronic pressure sensor to monitor and ad-
just cuff pressure on a moment-to-moment basis, and (2)
other more recently available devices use a pneumatic sys-
tem to maintain cuff pressure by applying a set pressure
through the pilot balloon and cuff inflation tubing. At the
time of this writing there have been three published stud-
ies that have explored the role of CPC with conventional
polyvinylchloride cuffs to reduce VAP. On one hand, a
small randomised controlled trial in Spain showed that
whilst CPC using a modified aquarium pump did prevent
falls in cuff pressure, this was associated with a small but
non-significant (from 29% to 22%, p = 0.44) lowering of
the incidence of clinical VAP [10]. On the other hand, a
quasi-randomised prospective observational study showed
a reduction in VAP from 22% to 11.2% (p = 0.02) associ-
ated with CPC using a commercially available electronic
cuff pressure controller [11]. Also, a small randomised
controlled trial in a single centre in France showed a sub-
stantial and significant reduction in the occurrence of
VAP during ICU stay from 26.2% to 9.8% (p = 0.032) asso-
ciated with a pneumatic cuff pressure controller providing
CPC [12]. The designs of these studies were not optimal;
all had small sample sizes, one used a very rudimentary
device design, only one looked at impact on antibiotic use
overall and none had blinded endpoint assessment despite
a clear risk of bias with unblinded endpoints using sub-
jective criteria. Despite these limitations, CPC appears to
show the most promise as a simple intervention with min-
imal impact on routine nursing practice to reduce VARI,
though higher-quality data are required to demonstrate its
impact conclusively.
To achieve a good understanding of the value of this
intervention and its cost-effectiveness, patients in the
present trial will be randomised to receive either auto-
mated continuous or manual control of cuff pressure
three times per day (current standard practice). This trial
will produce high-quality data to inform the future care of
ventilated patients in Vietnam and throughout the world.
Methods/design
Aims of the study
The aim of this trial is to determine if CPC can reduce
the incidence of VARI in adults. Secondary aims include
establishing whether CPC leads to an increase in
proportion of ICU days not on antibiotics or a reduction
in antibiotic costs, a reduction in the frequency of HAI
as a whole during ICU stay, length of ventilation, length
or cost of ICU and hospital stays, as well as any local
complications of the endotracheal cuff and mortality at
28 and 90 days post-randomisation and at discharge
from ICU and hospital.
Study design
The proposed study is an open-label, randomised con-
trolled trial comparing tracheal cuff CPC via an auto-
mated electronic device with intermittent manual
pressure control for the prevention of VARI in ICU. For
the purpose of this study a stand-alone CPC device
(reference 701; TRACOE medical GmbH, Nieder-Olm,
Germany) will be used for the intervention.
Study population
Patients are being recruited over an 18-month period
from the ICUs in the Hospital for Tropical Diseases
(HTD) and Trung Vuong Emergency Hospital (TVH) in
Ho Chi Minh City and the National Hospital of Tropical
Diseases (NHTD) in Hanoi. HTD and NHTD are refer-
ral centres for the management of patients with infec-
tious diseases. Both receive patients with infectious
diseases directly from their local populations as well as
patients transferred from other hospitals in southern
and northern Vietnam. TVH is a provincial hospital
serving the general medical needs of the local population
in Ho Chi Minh City.
Patients are considered eligible for inclusion in the
study when they are at least 18 years of age, have been
intubated for ≤ 24 h at the time of randomisation (either
oral or tracheostomal) and for active treatment (i.e.,
physician caring for patient would prescribe an antibiotic
if the patient developed an infection). Exclusion criteria
are previous enrolment in the study; having been previ-
ously intubated within the last 14 days; and known
tracheal stenosis, tracheomalacia or stridor that is sus-
pected secondary to physical tracheal injury. Patients are
enrolled only following written informed consent pro-
vided by themselves or their legal representatives.
Patients are stratified by clinical diagnosis as tetanus
or non-tetanus, because patients with tetanus represent
a distinct subgroup; usually they are without significant
premorbid disease or systemic inflammatory response,
undergo primary tracheostomy and have a prolonged
duration of intubation and ICU stay. Whilst rare in
high-income settings, in many countries patients with
tetanus represent a significant burden of disease with
high rates of HAI and high consumption of ICU re-
sources [13, 14]. Thus, a protocol that attempts to ad-
dress the problem of HAI in this setting also needs to
specifically address tetanus.
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Study endpoints
The primary endpoint is the occurrence of VARI which
is defined as VAP or ventilator-associated tracheobron-
chitis (VAT) during ICU stay up to a maximum of 90
days post-randomisation as evaluated by an independent
endpoint committee. For both VAP and VAT, it is a core
requirement for the patient to have been intubated for at
least 48 h and for the tube to have been in place within
the 48 h before the infection occurred. An additional
core criterion for all cases is that a decision has been
made to start new antibiotics or change the antibiotic
regimen to treat a new infection. In addition to these
core criteria, the endpoint diagnosis of VAT further re-
quires new onset of purulent respiratory secretions or
change in character of sputum or increase in volume of
sputum plus either (1) temperature > 38 °C or < 36 °C or
(2) white blood cell count < 4.0 × 109/L or ≥ 12 × 109/L
with no other recognised cause. The endpoint diagnosis
of VAP is met when the core criteria are met and there
are new or progressive changes visualised by chest
radiography plus two of following three criteria: (1)
temperature > 38 °C or < 36 °C, (2) white blood cell
count < 4.0 × 109/L or ≥ 12 × 109/L with no other
recognised cause, and (3) a new onset of purulent
respiratory secretions or change in character of sputum
or increase in volume of sputum.
Secondary endpoints include microbiologically con-
firmed VARI (defined as VARI plus bacterial growth of
≥ 105 colony-forming units/ml [endotracheal aspirate] or
equivalent semi-quantitative growth), clinical and micro-
biologically confirmed VAP, proportion of intubated days
receiving antibiotics, incidence of other HAI (as defined
by the European Centre for Disease Prevention and
Control [ECDC] criteria [15]) whilst intubated, total
number of days ventilated/in ICU, cost of ICU/hospital
stay, cost of antibiotics during ICU/hospital stay and
mortality at 28 and 90 days after randomisation as well
as at ICU and hospital discharge. Safety data, including
in-hospital re-intubation, tracheomalacia, tracheal sten-
osis and other local complications of endotracheal place-
ment, will be collected up to 90 days post-enrolment or
until hospital discharge, whichever is later. The time pe-
riods over which endpoints or censoring events will be
elicited are shown in Table 1.
Sample size
Based on local data and data derived from a large point
prevalence study in Vietnam [4], the estimated preva-
lence of VARI (the primary outcome) in non-tetanus
and tetanus ventilated patients is 20% and 30%, respect-
ively. We expect an effect size of a 50% reduction in
VARI using CPC, but we consider that a 40% reduc-
tion would be the minimum we would wish to detect
[11, 12]. This effect size is expected to be the same
in both tetanus and non-tetanus patients. To preserve
the generalisability of the study for settings where tet-
anus is less common whilst still demonstrating the
utility of the intervention in this patient group, we
will stratify randomisation to ensure that 30% of our
recruited patients will have a diagnosis of tetanus.
Thus we might expect to reduce VARI rates from
20% to 12% in non-tetanus patients and from 30% to
18% in tetanus patients. In a study population with
30% tetanus patients, this corresponds to an absolute
Table 1 Follow-up periods for all study endpoints
Endpoint Beginning of
follow-up
End of follow-up/censoring event
(soonest event applies, except where specified)
Primary
VARI Randomisation ICU discharge/death/transfer or 90 days
Secondary
Microbiologically confirmed VARI Randomisation ICU discharge/death/transfer or 90 days
Clinical and microbiologically confirmed VAP Randomisation ICU discharge/death/transfer or 90 days
Intubated days not receiving antibiotics Randomisation ICU discharge/death/transfer or 90 days
Incidence of HAI Randomisation Extubation/death/transfer/discharge from ICU or 90 days
Days ventilated/in ICU Randomisation ICU discharge, death, transfer
Cost of ICU stay ICU admission ICU discharge/death/transfer
Cost of antibiotics in ICU stay ICU admission ICU discharge/death/transfer
Cost of hospital stay Hospital admission Hospital discharge
28-Day mortality Randomisation 28 Days after randomisation
90-Day mortality Randomisation 90 Days after randomisation
ICU mortality Randomisation Discharge from ICU or death/palliative discharge from ICU
Hospital mortality Randomisation Discharge from hospital or death/palliative discharge from hospital
Abbreviations: VARI Ventilator-associated respiratory infection, ICU Intensive care unit, VAP Ventilator-associated pneumonia, HAI Hospital-acquired infection
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risk reduction from 23% to 13.8%. To detect this re-
duction with 80% power at the two-sided 5% signifi-
cance level, 278 patients are required in each arm.
Allowing for 8% loss to follow-up or early extubation
(before 48 h), we aim to recruit 600 patients in total
(420 non-tetanus, 180 tetanus). To our knowledge,
this will make it the largest single trial addressing the
prevention of VARI through CPC.
Randomisation procedure
Randomisation will be stratified 1:1 by site and whether
the patient has a clinical diagnosis of tetanus at the time
of randomisation. A stratified, computer-generated ran-
domisation list will be created using block randomisa-
tion with variable block length and incorporated into
secure internet-accessible software that implements the
randomisation. Once an eligible patient has consented,
the initials and date of birth of the patient will be en-
tered into the software by study staff. On the basis of the
randomisation list, the software will produce the treat-
ment allocation, which will be displayed and recorded in
the study database. All entries and outputs of the soft-
ware will be auditable.
Intervention
Depending on the results of randomisation, patients will
receive either manual, intermittent endotracheal cuff
pressure, which is checked and adjusted 8-hourly (stand-
ard care), or automatic, continuous endotracheal CPC
(intervention group). Cuff pressure will be recorded in
every ventilated patient every 8 h. Target pressure in
both groups will be 25 cmH2O as a default. Changes in
this target will be recorded, and the clinical reason for
the change will be noted.
Study assessment
On a daily basis, the attending physicians will assess
whether there is a new infection in a patient who has
been intubated for ≥ 48 h and in whom the tube is still
in place or has been removed within the previous 48 h.
If the answer is ‘yes’, a standard battery of tests, includ-
ing complete blood count, procalcitonin, arterial blood
gas, blood culture, sputum/endotracheal aspirate micros-
copy and culture, urine culture and chest x-ray, will be
performed regardless of the suspected site of infection.
Test results and clinical details from up to 5 days previ-
ous, the day of the HAI evaluation and the subsequent 2
days will be collected, including maximum/minimum
temperature, changes in ventilation parameters (fraction
of inspired oxygen, positive end-expiratory pressure),
changes in sputum colour or volume, and new inotrope
or vasopressor requirements. The treating clinicians will
provide their own diagnosis of the aetiology of the infec-
tion according to ECDC criteria and will prescribe
antibiotic and other therapies as per routine care. How-
ever, for the primary endpoint, an endpoint review com-
mittee, blinded to the treatment allocation and
independent of clinical involvement with the patient, will
review the complete case report form (CRF) and radi-
ology of patients completing the study at the end of each
month to determine whether they met the primary or
appropriate secondary endpoint criteria.
Enrolled patients will have cuff pressure controlled in
accordance with the allocated study arm for the entire
duration of their intubated time on ICU. Follow-up for
the primary outcome will be until transfer to another fa-
cility, death, discharge from ICU or 90 days following
randomisation, whichever is soonest. Patients who re-
quire re-intubation during the same stay in ICU will
continue in the study, using the same cuff pressure con-
trol measures originally allocated to them. Patients dis-
charged from ICU but requiring return to ICU and re-
intubation will not be re-enrolled and will be managed
in accordance with standard care. At the end of the hos-
pital stay the costs of the stay as billed will be recorded
(including bed, ventilator and other supportive therapy
costs, drugs including antibiotic costs, but not including
labour as per Vietnamese Ministry of Health guidance).
Additionally, as part of secondary endpoint assessment,
study staff will telephone patients or their relatives at 28
and 90 days after randomisation if they are no longer in-
patients in order to assess mortality and complications
related to intubation. A flowchart of study procedures is
shown in Fig. 1; a schedule of enrolment, interventions
and assessments is provided in Fig. 2.
Data management
Relevant data will be recorded onto a CRF and checked
for accuracy. After the follow-up is finished the CRFs
will be de-identified by removing patient identifiers and
telephone numbers. Selected staff will be trained in how
to enter all clinical data from the CRFs and from labora-
tory source documents into a computerised data entry
system using double data entry. Data will be retained for
≥ 15 years on completion of the study (last patient
followed for 90 days). Original paper documents will be
maintained for ≥ 5 years; thereafter digital copies will be
retained. All stored records will be kept secure and
confidential.
All personal information reviewed as part of this study
will remain confidential. Patient names or identifiers will
not appear in any database. Any scientific publications
or reports will not include information that can identify
any patient. Oxford University Clinical Research Unit
(OUCRU) is committed to open access to study data
and is working with its partners to facilitate mechanisms
to enable this.
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Statistical analysis
The details regarding all planned analyses will be elabo-
rated in an analysis plan prior to analysis. Reporting of the
trial results will clearly indicate which analyses were part
of this plan and which were not. The effect of the inter-
vention on the primary outcome will be quantified in an
intention-to-treat analysis that allocates all patients ac-
cording to the randomised treatment arm. The primary
endpoint will additionally be analysed in a per-protocol
analysis which will exclude patients not fulfilling the eligi-
bility criteria and patients intubated for < 48 h.
The primary endpoint will be analysed using a logistic
regression model with the randomised arm as the main
covariate and adjustment for tetanus status. Patients who
are intubated for < 48 h will be regarded as not having
reached the primary endpoint. Potential heterogeneity of
the intervention effect will be assessed on the basis of ap-
propriate interaction (likelihood ratio) tests and the prede-
fined subgroups, including (1) patients with and without
tetanus, (2) patients intubated for ≤ 2 and > 2 h before
randomisation, (3) patients with and without tracheos-
tomy and (4) hospital site.
Binary secondary endpoints (clinical and microbio-
logically confirmed VAP) will be analysed in the same
way as the primary endpoint. Both the distribution of
duration of ventilation (i.e., time to extubation) and the
time of ICU stay will be estimated. Death will be consid-
ered as a competing event; hence we will estimate the
cause-specific cumulative incidence. Cause-specific cu-
mulative incidence functions will be compared between
the arms using a Fine-Gray regression model with the
treatment arm as the main covariate and adjustment for
Fig. 1 Flowchart of study procedures
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tetanus status. Mortality will be visualised in each arm
(overall and by tetanus status) using Kaplan-Meier curves
and modelled using Cox regression. The proportion of
intubated days free of antibiotics will be analysed using a
Poisson regression model with the number of intubated
days without antibiotics as the outcome, the randomised
arm as the main covariate, and the (log-transformed) total
number of intubated days as an offset. Quasi-likelihood
will be used to account for potential over-dispersion.
The frequency of adverse events will be summarised
(in terms of both the total number of events and the
number of patients with at least one event). The propor-
tion of patients with at least one adverse event (overall
and for each specific event separately) will be sum-
marised and (informally) compared between the two
treatment groups using Fisher’s exact test.
Reporting of adverse events and monitoring
Because adverse events are relatively common in critic-
ally ill patients intubated in the ICU, safety reporting
will focus on events of potential relevance to cuff pres-
sure control. The events being reported to the ethics
committees are (1) all unexpected serious adverse
events, (2) all serious adverse events judged to be re-
lated or possibly related to cuff pressure and (3) all
deaths or palliative discharges (discharge to home of a
patient where ongoing care was considered futile to
permit the patient to die at home, a commonly pre-
ferred alternative to dying in hospital in Vietnam).
Reporting to the ethics committees will be done in
accordance with good clinical practice.
An independent data and safety monitoring board
(DSMB) has been established, consisting of expert
Fig. 2 Schedule of enrolment, interventions and assessments. HAI Hospital-acquired infection, ICU Intensive care unit, APACHE Acute Physiology
and Chronic Health Evaluation, PEEP Positive end-expiratory pressure, FiO2 Fraction of inspired oxygen, HbA1c Glycated haemoglobin,
VARI Ventilator-associated respiratory infection, PPI Proton pump inhibitor
Dat et al. Trials  (2018) 19:217 Page 7 of 10
Vietnamese and international researchers and doctors
with the necessary clinical, research and statistical know-
ledge. The DSMB has reviewed the protocol, and a
DSMB charter outlines its responsibilities and how it
operates. All DSMB reports will be sent to the respon-
sible ethics committees, including the site ethics com-
mittees and the Oxford Tropical Research Ethics
Committee, for consideration. Recruitment will continue
at active sites during the DSMB review period. No in-
terim analyses are planned for the primary endpoint;
however, safety analyses will be conducted after 30 pa-
tients have been recruited and subsequently at points
decided by the DSMB.
The study will be monitored by a team at OUCRU, in-
dependent of study design and management. Central
monitoring will take place regularly. On-site monitoring
occurred after the recruitment of 25 patients in total,
with a second monitoring visit planned after recruitment
of 200 patients, and further monitoring will be sched-
uled depending on the results of early monitoring visits.
The SPIRIT (Standard Protocol Items: Recommenda-
tions for Interventional Trials) for this research is avail-
able in Additional file 1.
Discussion
To our knowledge, this is the first study with an ad-
equate sample size and robustly designed endpoints to
evaluate the effectiveness of endotracheal cuff CPC in
preventing VARI. It also concurrently measures the im-
pact of the intervention on important patient-centred
clinical outcomes and important outcomes concerning
antibiotic use. An ideal intervention should, in addition
to an impact on the primary outcome (VARI episodes),
show resultant benefits in reducing mortality, duration
of mechanical ventilation and ICU stay in association
with reducing antibiotic use, as recently recommended
for antibiotic stewardship programmes [16]. The
intervention will likely be considered of questionable
benefit should it result only in a reduction in VARI
episodes without corresponding reductions in at least
some of these patient-centred or antibiotic steward-
ship outcomes.
Leakage of secretions through the endotracheal tube
cuff is commonplace in clinical practice with intermit-
tent cuff pressure monitoring [17]. Approaches to
prevent aspiration of contaminated oropharyngeal se-
cretions by maintaining endotracheal cuff pressure have
been studied in an effort to reduce VAP rate and its as-
sociated mortality. However, previous studies (small
and non-randomised controlled trials) have not estab-
lished a sufficient evidence base on which to recom-
mend CPC routinely [18, 19]. This study provides an
opportunity to evaluate the impact of CPC in prevent-
ing VARI and in reducing antibiotic use as an aspect of
antimicrobial stewardship in a resource-constrained
setting with established high levels of antibiotic use and
resistance.
Pathogen colonisation of the trachea and endotracheal
tube may progress to VAT, which can be a transitional
stage before development of VAP. Both VAT and VAP
share common clinical manifestations of fever, purulent
respiratory secretions, and leucocytosis with the distin-
guishing presence of pulmonary infiltrates on chest x-
rays in VAP. In a prospective study in 10 countries with
114 ICUs, incidence of VAT was similar to VAP (11% vs
12%) [20]. However, VAT is often a predisposing factor
for development of VAP, and appropriate antibiotic
treatment for VAT can reduce the progression to VAP
[20, 21]. In a survey of perceptions of international phy-
sicians, nearly 80% of respondents diagnosed VAT on
the basis of both clinical and microbiological criteria,
and the remaining respondents used clinical criteria
alone or as a diagnosis of exclusion. Half of the respon-
dents agreed to antibiotic use in patients with VAT [22].
In Vietnam it is common practice to treat VAT, and in
view of these considerations, we constructed our trial
around an endpoint that encompassed both VAT and
VAP, in contrast to other studies [10–12]. Although rec-
ognition of VAT and intervention at this stage are ex-
pected to impact the mortality, length of stay and
treatment cost which would be attributed to VAP, it is
clear that there are important differences between sur-
veillance definitions and actual clinical definitions on
which treatment is based.
In an open-label study where the treating doctor is not
blinded to the intervention, there is a risk of clinical as-
certainment bias of the study endpoint [23]. Whilst
death or microbiological results are hard endpoints
which are unlikely to be biased by a lack of blinding,
VARI diagnostic categories and antibiotic use are more
subjective and vulnerable to misclassification bias in
non-blinded trials [24]. For this reason an independent
endpoint committee is recommended for multicentre
clinical trials to judge complex, multi-aspect definitions
and outcomes [25, 26]. In our study treating doctors
know the allocated arm of the patient and perform as-
sessments for HAI as part of routine care; therefore the
use of a blinded endpoint committee will reduce bias in
the primary endpoint evaluation. The study may also
offer an opportunity to understand inconsistencies in
the assessment of VARI diagnoses between treating doc-
tors and the endpoint committee, and within the end-
point committee, as well as how this impacts the
significance of results.
A future consideration would be to evaluate the im-
pact of a successful intervention at the ICU level, on the
speed at which resistance develops in the unit, with the
hope that a substantial reduction in the use of antibiotics
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would be reflected in slower development of resistance
in the ICU as a whole. This would require a cluster-
randomised or stepped-wedge design, and such an ap-
proach should be considered for any potential rollout of a
successful intervention. Given the crisis in antibiotic resist-
ance, this would provide valuable additional information
not attainable through an individual patient randomised
trial design to complement the results of this study.
Trial status
The trial is currently recruiting. Important protocol
amendments will be communicated to relevant bodies
(investigators, institutional review boards, DSMB, jour-
nals) by Dr. B. Nadjm, trial principal investigator, as
soon as changes are made.
Trial sponsor
Oxford University - Centre for Tropical Medicine
(sponsor’s reference R45398/RE001). Contact: Evelyne
Kestelyn, 764 Vo Van Kiet Street, Ward 1, District 5, Ho
Chi Minh City, Vietnam. Telephone: + 84 8 39237954.
Email: info@oucru.org. The sponsor has specialised insur-
ance to cover any potential harm caused as a result of par-
ticipation in the study.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
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